New scan could reveal hidden spread of prostate cancer
NCT ID NCT06074510
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study is testing whether a special PET scan using PYLARIFY can find prostate cancer that has spread beyond the prostate in men with favorable intermediate risk cancer. About 274 men will receive one injection and scan, then be followed for up to a year. The goal is to see if the scan detects cancer that other tests miss, which could help guide treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Piflufolastat F 18 (PYLARIFY injection)
What this could lead to
If successful, this could help doctors more accurately determine if prostate cancer has spread, leading to better treatment choices for men with favorable intermediate risk prostate cancer.
What could go wrong
This is a phase 4 imaging study, not a treatment trial. It may not change outcomes for all patients, and false positives or negatives are possible. Results are limited to detection, not cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BAMF Health
Grand Rapids, Michigan, 49503, United States
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Hoag Cancer Center
Irvine, California, 92618, United States
-
Huntsman Cancer Institute University of Utah
Salt Lake City, Utah, 84112, United States
-
Johns Hopkins University
Baltimore, Maryland, 21205, United States
-
Karmanos Cancer Institute Wayne State University
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
Tower Urology
Los Angeles, California, 90048, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
University of California San Francisco
San Francisco, California, 94158, United States
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States